One of the biggest shifts in Alzheimer’s medicine right now is not a drug. It is a blood draw. Reading the actual biology of the disease used to mean a lumbar puncture (a needle into the spinal fluid) or an expensive, not-always-available PET scan. A blood marker called p-tau217, a phosphorylated tau-protein fragment that tracks Alzheimer-related tau and amyloid biology, now flags whether amyloid is building in the brain with an accuracy (AUC) around 0.95, roughly on par with spinal-fluid testing. Confirming that biology used to mean a lumbar puncture or a PET scan (positron emission tomography, a tracer image of a biological process). That changes who can be checked, how early, and how easily.
What this page answers
- What Alzheimer blood biomarkers measure
- What an abnormal result can and cannot diagnose
- Who should consider testing with a clinician
What a biomarker is, and why it matters
A biomarker is a measurable signal of an underlying biological process. In Alzheimer’s, the markers that count reflect the disease’s two hallmarks: amyloid plaques and tangles of a protein called tau. Think of them as a smoke detector for the disease, picking up the chemistry before the fire of symptoms is obvious. Here is what you will actually hear about:
| Marker | What it reflects | Where it stands |
|---|---|---|
| p-tau217 | Amyloid and tau pathology together | The standout; classifies amyloid/tau status with about 90 to 95% accuracy, matching or beating FDA-approved spinal-fluid tests |
| Amyloid-beta 42/40 ratio | Amyloid status | Useful, but ε4 can skew some plasma assays (see below) |
| GFAP | Reactive astrocytes (brain inflammation) | Adds context |
| NfL | General neuronal injury, any cause | Tracks neurodegeneration, not specific to Alzheimer’s |
A carrier-specific catch is worth knowing on the amyloid-beta 42/40 ratio. Because APOE genotype itself influences how the brain handles amyloid, ε4 can nudge some plasma Aβ42/40 readings somewhat independently of how much amyloid is actually in your brain. That is one reason p-tau217 has become the preferred standalone blood marker.
These markers map onto the ATN framework clinicians use, which stands for Amyloid, Tau, and Neurodegeneration. That scaffolding sits behind the 2024 revised Alzheimer’s diagnostic criteria, which for the first time accept blood biomarkers for diagnosis. The reason any of this matters: Alzheimer’s pathology can begin years before symptoms, so a marker that flags it earlier opens a longer window to act and to match people to the right treatments.
The shift underway
Blood tests for these markers used to lag well behind spinal-fluid testing, but the methods have improved fast, and this is no longer hypothetical. The clearest evidence is for p-tau217: a 2024 Nature Medicine study found it classified amyloid and tau status with accuracy in the 90 to 95% range (area-under-the-curve roughly 0.93 to 0.96), performing similar or superior to FDA-approved clinical spinal-fluid tests, and it also tracks who is more likely to decline. In May 2025 the FDA cleared the first blood test for Alzheimer’s, a plasma p-tau217/Aβ42 ratio (Fujirebio’s Lumipulse), for adults 55 and older with cognitive symptoms. The appeal is obvious: a blood test is cheaper, less invasive, and far more scalable than spinal fluid or PET. Used well, blood biomarkers help clinicians work up memory complaints sooner and identify the right candidates for biomarker-confirmed treatments like the anti-amyloid drugs.
A marker is not a diagnosis
This is an exciting moment, which is exactly when it pays to stay grounded.
- A biomarker is not a diagnosis. These tests reflect biology; interpreting them takes clinical context, and the standards for who should be tested and how to act are still maturing. Current guidance generally supports use in people with cognitive symptoms, not for screening the healthy.
- Performance varies by test, lab, and population, and the field is still sorting out which assays and thresholds to trust.
- Screening healthy people is not established. Learning you have amyloid biology without symptoms, and often without a clear action beyond what you would already be doing, carries real psychological weight. This is a decision for you and a clinician, not a curiosity buy, and definitely not a direct-to-consumer impulse.
Better tools are coming; screening healthy carriers is not
If you are an APOE4 carrier, the headline is hopeful: the tools to detect and track this disease are getting dramatically better, which strengthens the case for engaging early. A 2025 Brain study also found that the same p-tau217 level may mark earlier tau spread in carriers, especially people with two copies, which is a reason for specialists to read a result in genotype context rather than against a one-size cut-off. That analysis is in APOE4 lowers the p-tau217 threshold for tau spread. But “better tools are coming” is not the same as “go get tested today.” For now, talk to a clinician about whether any biomarker testing fits your situation, and keep pulling the modifiable levers regardless, since those do not wait on a lab result.
Common questions
Is a blood biomarker the same as the APOE test? No, and the difference matters. APOE genotyping tells you a risk factor you were born with. Blood biomarkers tell you whether disease biology is present right now. They answer different questions.
Should I act on a positive result? Only with clinical guidance. A marker is one input. What to do depends on symptoms, context, and your goals, and for now the levers you control matter regardless.
The tools are improving fast, which is genuinely good news, but better tools are not the same as “test everyone today.”